Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oseltamivir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.88 |
| ▸ | LMNA | P02545 | 1/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.88 |
| ▸ | NEU1 | Q99519 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oseltamivir SCHEMBL13459830 | 1.00 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL19513553 | 1.00 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL32035 | 1.00 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL14283136 | 1.00 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL14775954 | 1.00 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL18379765 | 1.00 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL125557 | 1.00 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL28487532 | 0.99 | MEN1 (0.86) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL9281280 | 0.99 | MEN1 (0.86) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL28299858 | 0.99 | MEN1 (0.86) | MEN1LMNACYP3A4KMT2ANEU1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180207145-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED | 2018-07-26 | — | — | US | disclosed |
| US-20180207145-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED | 2018-07-26 | — | — | US | disclosed |
| US-20170100385-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2017-04-13 | — | — | US | disclosed |
| US-20170100385-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2017-04-13 | — | — | US | disclosed |
| US-9585845-B2 | Oral pharmaceutical composition comprising oseltamivir and method of preparing the same | ZHONGSHUAI PHARMACEUTICAL SCI & TECH CO., LTD. (CN) | 2017-03-07 | — | — | US | disclosed |
| US-9585845-B2 | Oral pharmaceutical composition comprising oseltamivir and method of preparing the same | ZHONGSHUAI PHARMACEUTICAL SCI & TECH CO., LTD. (CN) | 2017-03-07 | — | — | US | disclosed |
| US-20160120820-A1 | ORAL PHARMACEUTICAL COMPOSITION COMPRISING OSELTAMIVIR AND METHOD OF PREPARING THE SAME | ZHONGSHUAI PHARMACEUTICAL SCI & TECH CO., LTD. (CN) | 2016-05-05 | — | — | US | disclosed |
| US-20160120802-A1 | ORALLY-DISINTEGRATING OSELTAMIVIR TABLET AND METHOD FOR PREPARING THE SAME | Zhongshuai Pharmaceutical Sci & Tech Incorporated Co., Ltd. (CN) | 2016-05-05 | — | — | US | disclosed |
| US-20160120802-A1 | ORALLY-DISINTEGRATING OSELTAMIVIR TABLET AND METHOD FOR PREPARING THE SAME | Zhongshuai Pharmaceutical Sci & Tech Incorporated Co., Ltd. (CN) | 2016-05-05 | — | — | US | disclosed |
| US-20160120820-A1 | ORAL PHARMACEUTICAL COMPOSITION COMPRISING OSELTAMIVIR AND METHOD OF PREPARING THE SAME | ZHONGSHUAI PHARMACEUTICAL SCI & TECH CO., LTD. (CN) | 2016-05-05 | — | — | US | disclosed |
| WO-2015173701-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATING INFECTIOUS DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2015-11-19 | — | — | WO | disclosed |
| US-8569255-B2 | Post-exposure therapy of influenza A infections | HER MAJESTY THE QUEEN IN RIGHT OF CANADA, AS REPRESENTED BY THE MINISTER OF NATIONAL DEFENCE (CA) | 2013-10-29 | — | — | US | disclosed |
| US-20120195960-A1 | POST-EXPOSURE THERAPY OF INFLUENZA A INFECTIONS | HER MAJESTY THE QUEEN IN RIGHT OF CANADA, AS REPRESENTED BY THE MINISTER OF NATIONAL DEFENCE (CA) | 2012-08-02 | — | — | US | disclosed |
| US-7527934-B2 | Labeled substrate conjugates for identifying enzyme inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-05-05 | — | — | US | disclosed |
| US-20060057658-A1 | Labeled substrate conjugates for identifying enzyme inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207145-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES | DDOST, DHX30, DDX5 | MEN1 3674/4885LMNA 2832/4885CYP3A4 2446/4885 |
| US-20160120802-A1 | ORALLY-DISINTEGRATING OSELTAMIVIR TABLET AND METHOD FOR PREPARING THE SAME | TAS2R40, TAS2R30, TAS2R60 | MEN1 2489/4885LMNA 828/4885CYP3A4 464/4885 |
| US-20160120820-A1 | ORAL PHARMACEUTICAL COMPOSITION COMPRISING OSELTAMIVIR AND METHOD OF PREPARING THE SAME | WASHC4, SEM1, VMA21 | MEN1 3850/4885LMNA 1775/4885CYP3A4 15/4885 |
| US-20170100385-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES | DDOST, DHX30, DDX5 | MEN1 3674/4885LMNA 2832/4885CYP3A4 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.